Barr Pharmaceuticals Inc.  (BRL) Trade Now »     Rate BRL  -  Discuss BRL  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

BRL: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Teva Beats on Profits: A Biogeneric Boon in '09? BRL

76%

+3.72% in 17 days Teva Beats on Profits: A Biogeneric Boon in '09? Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than dou ... Continue reading »

Updated FDA Calendar of 72 Decision Dates BRL

76%

-0.63% in 7 days (closed on 11/06/08) Updated FDA Calendar of 72 Decision Dates The accompanying table [click to enlarge image] presents an updated calendar of expected FDA decision dates, including a new NDA filing by Johnson & Johnson (JNJ) for Comfyde and recent approval for Barr Pharma's (BRL) low-dose birth control pill Lo-Seasonique. Teva Pharma (TEVA) has closed a deal with Barr's unsecured credit holders in an effort to close its proposed $7.5B acquisition by year-end, which will expand Teva's generic drug business and also add to its line-up of brand name medications through Barr's ... Continue reading »

Teva is on Target to Acquire Barr BRL

76%

+1.31% in 15 hours (closed on 10/30/08) Teva is on Target to Acquire Barr The accompanying table [click to enlarge image] presents an updated calendar of expected FDA decision dates, including a new NDA filing by Johnson & Johnson (JNJ) for Comfyde and recent approval for Barr Pharma's (BRL) low-dose birth control pill Lo-Seasonique. Teva Pharma (TEVA) has closed a deal with Barr's unsecured credit holders in an effort to close its proposed $7.5B acquisition by year-end, which will expand Teva's generic drug business and also add to its line-up of brand name medications through Barr's strong presenc ... Continue reading »

BRL is a HOLD BRL

5 %

+23.77% in 521 days Traders at Palma are Neutral on BRL www.palmaresearch.com/default.aspx?viewreport=BRL   Continue reading »

From the Blogosphere

ETF Investing: We Get Sick In Recessions! XPH and IHI Healthcare Stocks

Filed under: Pfizer (PFE), Getting started, Johnson and Johnson (JNJ), Boston Scientific (BSX), Bristol-Myers Squibb (BMY), Merck and Co (MRK), Watson Pharmaceuticals (WPI), ETF Investing It's one of those unfortunate facts of life, everyone is going to get sick at some time in their lives. It could be something as simple as the common cold or a complex series of symptoms that takes years to diagnose. The upside of all of this is that the medical business is a relatively safe bet when it comes to investments. If you see the benefit of this and want to put some money into a health care relate... Continue reading »

Teva Beats on Profits: A Biogeneric Boon in '09?

76%

Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than doubled from 3Q07 at $710M. Teva also expects to close its acquisition of Barr Ph ... Continue reading »

A Bullish Outlook for Generic Drugs After Election

76%

In addition to the favorable underlying trends I wrote about previously for the generic drug industry, both presidential candidates are bullish on the industry with the following excerpts taken directly from their websites: Senator Obama: Lower drug costs by allowing the importation of safe medicines from other developed countries, increasing the use of generic drugs in public programs and taking on drug companies that block cheaper generic medicines from the market. Senator McCain: Reduce drug costs by allowing greater use of generics (including bio-generics). The accompanying table highlight... Continue reading »

Teva is on Target to Acquire Barr

76%

The accompanying table [click to enlarge image] presents an updated calendar of expected FDA decision dates, including a new NDA filing by Johnson & Johnson (JNJ) for Comfyde and recent approval for Barr Pharma's (BRL) low-dose birth control pill Lo-Seasonique. Teva Pharma (TEVA) has closed a deal with Barr's unsecured credit holders in an effort to close its proposed $7.5B acquisition by year-end, which will expand Teva's generic drug business and also add to its line-up of brand name medications through Barr's strong presence in birth control. Continue reading »

Generic Drug Industry Outpaces Drug & Healthcare ETFs

76%

The accompanying table presents statistics and the top five rated companies in the ETFI Global Generic Drug Index, which includes a total of 44 companies. Over the past year, generic drug companies have outpaced both the Healthcare Sector SPDR (XLV) and existing drug ETFs such as PowerShares Dynamic Pharma (PJP), Pharma HOLDRs (PPH), iShares Dow Jones US Pharma (IHE), and the S&P Pharma SPDR (XPH). All of the top five rated generic drug companies and over two-thirds of the 44 companies in the index are based outside of the United States; so a Global Generic Drug ETF would provide investors w... Continue reading »

Trade BRL Now
and Get 30 Free Trades »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.